Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder

First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+

FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension

WINREVAIR is a breakthrough biologic for this rare, progressive disease

Warren Remedies commences commercial production of APIs

AstraZeneca Pharma India appoints Vinay Sharma as Business Unit Head - Rare Disease

Currently, Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology

Zydus receives tentative approval from USFDA for Letermovir Tablets

Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)

Celanese and Secarna Pharmaceuticals collaborate for RNA research for antisense therapies

Bristol Myers Squibb completes acquisition of Karuna Therapeutics

KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia

Elegen launches Enfina DNA enhancement for rapid synthesis of highly complex DNA

Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days

Aurobindo Pharma receives USFDA approval for Mometasone Furoate Monohydrate nasal spray

The approved product has an estimated market size of US$ 44.5 million for the twelve months ending January 2024

Apollo appoints Dr. Madhu Sasidhar as President & CEO, Hospitals Division

Dr Madhu will oversee Apollo's hospital business and will focus on continuing to deliver the world's best clinical outcomes